Promising Outlook for aTyr Pharma’s Efzofitimod and Strong Financial Position Reinforce Buy Rating

Analyst Derek Archila of Wells Fargo maintained a Buy rating on aTyr Pharma (ATYR – Research Report), retaining the price target of $17.00.

Derek Archila’s rating is based on the promising outlook for aTyr Pharma’s lead drug candidate, efzofitimod, which is currently in Phase 3 trials for treating pulmonary sarcoidosis. The anticipation of favorable results from this trial in the third quarter of 2025 contributes significantly to the positive sentiment surrounding the stock.
Additionally, the company’s strong cash position, with $79 million at the end of the first quarter of 2025, provides a solid financial runway to support operations through the expected data release. This financial stability, coupled with the potential market impact of efzofitimod, underpins the Buy rating and reinforces the stock as a top pick.

In another report released on April 29, H.C. Wainwright also reiterated a Buy rating on the stock with a $35.00 price target.

Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ATYR in relation to earlier this year.